MicroRNA-155 Hallmarks Promising Accuracy for the Diagnosis of Various Carcinomas: Results from a Meta-Analysis

作者：Wu, Chuancheng; Liu, Qiuyan; Liu, Baoying^*

来源：Disease Markers, 2015, 2015: 1-12.

DOI：10.1155/2015/327287

• BREAST-CANCER
• POTENTIAL BIOMARKER
• CIRCULATING MICRORNAS
• CLINICAL-SIGNIFICANCE
• PLASMA MICRORNAS
• LUNG-CANCER
• SERUM
• EXPRESSION
• MIR-155
• IDENTIFICATION

Background. Recent studies have shown that microRNAs (miRNAs) have diagnostic values in various cancers. This meta-analysis seeks to summarize the global diagnostic role of miR-155 in patients with a variety of carcinomas. Methods. Eligible studies were retrieved by searching the online databases, and the bivariate meta-analysis model was employed to generate the summary receiver operator characteristic (SROC) curve. Results. A total of 17 studies dealing with various carcinomas were finally included. The results showed that single miR-155 testing allowed for the discrimination between cancer patients and healthy donors with a sensitivity of 0.82 (95% CI: 0.73-0.88) and specificity of 0.77 (95% CI: 0.70-0.83), corresponding to an area under curve (AUC) of 0.85, while a panel comprising expressions of miR-155 yielded a sensitivity of 0.76 (95% CI: 0.68-0.82) and specificity of 0.82 (95% CI: 0.770.86) in diagnosing cancers. The subgroup analysis displayed that serum miR-155 test harvested higher accuracy than plasma-based assay (the AUC, sensitivity, and specificity were, resp., 0.87 versus 0.73, 0.78 versus 0.74, and 0.77 versus 0.70). Conclusions. Our data suggest that single miR-155 profiling has a potential to be used as a screening test for various carcinomas, and parallel testing of miR-155 confers an improved specificity compared to single miR-155 analysis.

• 出版日期2015
• 单位福建医科大学